The Utility of Molecular Tumor Profiling for Patients With Advanced or Rare Cancer in a Regional Australian Setting
While somatic mutations are common and trials are available for patients with advanced and/or rare cancer, trials administered locally are favored, and cost savings may contribute to this.
Authors
- Craig R. Underhill (ORCID: https://orcid.org/0000-0001-9335-2678)
- D. Thomas
- Ortis Estacio (ORCID: https://orcid.org/0009-0009-1237-509X)
- Richard Wilhelm Eek (ORCID: https://orcid.org/0000-0003-2357-1781)
- Natalie Chilko (ORCID: https://orcid.org/0000-0002-8340-5761)
- Christopher Steer (ORCID: https://orcid.org/0000-0002-7677-3339)
- Kerrie Clarke
- Jacqueline McBurnie
Institutions
- Barwon Health (AU)
- Garvan Institute of Medical Research (AU)
- La Trobe University (AU)
- Geelong Hospital (AU)
- UNSW Sydney (AU)
- Albury Wodonga Health (AU)
- St Vincent's Clinic (AU)
Publication Details
- Journal
- Asia-Pacific Journal of Clinical Oncology
- Published
- 2025-12-30
- DOI
- https://doi.org/10.1111/ajco.70059
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00